RESUMEN

BACKGROUND: Sirolimus constitutes a safe and effective treatment for cardiac manifestations of tuberous sclerosis complex (TSC) in children but only four cases describing prenatal treatment of rhabdomyomas with mTOR inhibitors have been published. CASE: In this case, sirolimus was initiated at 26 weeks´ gestation in a pregnant woman with TSC with a fetus with a large rabdomyoma conditioning severe arrythmia. There was a significant reduction in the tumor size with ongoing treatment and a partial reversion of the arrythmia. CONCLUSION: m-TOR inhibitors can be considered for severe cases of fetal rhabdomyomas with poor prognosis given its potencial benefits.

Asunto(s)

Neoplasias Cardíacas , Rabdomioma , Esclerosis Tuberosa , Niño , Femenino , Humanos , Embarazo , Arritmias Cardíacas , Feto/patología , Neoplasias Cardíacas/tratamiento farmacológico , Neoplasias Cardíacas/patología , Rabdomioma/tratamiento farmacológico , Rabdomioma/patología , Sirolimus/uso terapéutico , Esclerosis Tuberosa/complicaciones , Esclerosis Tuberosa/tratamiento farmacológico